Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Down – Time to Sell?

Bicara Therapeutics Inc. (NASDAQ:BCAX)’s stock price gapped down prior to trading on Friday . The stock had previously closed at $16.60, but opened at $16.01. Bicara Therapeutics shares last traded at $16.27, with a volume of 5,771 shares traded.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on BCAX shares. Stifel Nicolaus started coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They set a “buy” rating and a $47.00 price target for the company. Morgan Stanley began coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set an “overweight” rating and a $35.00 target price for the company. Rodman & Renshaw assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price target on the stock. Cantor Fitzgerald started coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set an “overweight” rating for the company. Finally, HC Wainwright initiated coverage on Bicara Therapeutics in a report on Friday, December 6th. They issued a “buy” rating and a $42.00 target price on the stock. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $43.00.

Bicara Therapeutics Stock Performance

The business’s fifty day moving average is $20.81.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). Analysts predict that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bicara Therapeutics

A number of hedge funds have recently made changes to their positions in the business. RA Capital Management L.P. purchased a new position in Bicara Therapeutics in the 3rd quarter worth approximately $177,169,000. FMR LLC purchased a new position in shares of Bicara Therapeutics in the third quarter worth $57,913,000. Braidwell LP bought a new position in shares of Bicara Therapeutics during the third quarter worth $42,219,000. Janus Henderson Group PLC purchased a new position in Bicara Therapeutics during the third quarter valued at $30,329,000. Finally, Baker BROS. Advisors LP purchased a new position in Bicara Therapeutics during the third quarter valued at $21,225,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.